The information was generated by an EvaluatePharma analysis cited by Pharm Exec magazine.
Pfizer ($45.3 billion in Rx sales)
1. Prevnar 13 ($5.8 billion)
2. Lyrica ($4.97 billion)
3. Ibrance ($4.12 billion
Roche ($44.55 billion in Rx sales)
1. Herceptin ($7.14 billion)
2. Avastin ($7 billion)
3. Rituxan (6.91 billion)
Novartis ($43.48 billion in Rx sales)
1. Gilenya ($3.34 billion)
2. Cosentyx ($2.84 billion)
3. Lucentis ($2.05 billion)
Johnson & Johnson ($38.82 billion in Rx sales)
1. Stelara ($5.16 billion)
2. Remicade ($4.89 billion)
3. Zytiga ($3.5 billion)
Merck & Co. ($37.35 billion in Rx sales)
1. Keytruda ($7.17 billion)
2. Januvia (3.69 billion)
3. Gardasil ($3.15 billion)
Sanofi ($35.12 billion in Rx sales)
1. Lantus ($4.21 billion)
2. Pentacel ($2.07 billion)
3. Fluzone ($2.02 billion)
AbbVie ($32.07 billion in Rx sales)
1. Humira ($19.94 billion)
2. Mavyret ($3.44 billion)
3. Imbruvica ($2.97 billon)
GlaxoSmithKline ($30.65 billion in Rx sales)
1. Triumeq ($3.54 billion)
2. Advair ($3.23 billion)
3. Tivicay ($2.19 billion
Amgen ($22.53 billion in Rx sales)
1. Enbrel ($5.01 billion)
2. Neulasta ($4.48 billion)
3. Prolia ($2.29 billion)
Gilead Sciences ($21.68 billion in Rx sales)
1. Genvoya ($4.62 billion)
2. Truvada ($2.3 billion)
3. Epclusa ($1.97 billion)
More articles on pharmacy:
Sanofi poaches exec from Novartis
Eli Lilly’s migraine drug 1st approved to reduce cluster headaches: 4 notes
EpiPen shortage will drag on: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
